سعر جينيلوكيم 300مكجم فيال 2025

Filgrastim (recombinant human granulocyte colony-stimulating factor) 300 mcg injection vial made by Shandong Geneleuk Biopharmaceutical (China) and listed in Egypt with United Partners Company; used to stimulate neutrophil production.

• Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.Population: Adults and childrenDailyMed (U.S. National Library of Medicine)
• Reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy in acute myeloid leukaemia.Population: Adults and childrenDailyMed (U.S. National Library of Medicine)
• Reduce the duration of neutropenia and neutropenia-related events in non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.Population: Adults and childrenDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions in patients receiving myelosuppressive chemotherapy: pyrexia, pain, rash, cough and dyspnoea; bone pain is common in progenitor cell donors.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• History of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim or pegfilgrastim.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Splenic rupture, including fatal cases, can occur; evaluate patients reporting left upper abdominal or shoulder pain.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Acute respiratory distress syndrome, serious allergic reactions including anaphylaxis, severe sickle cell crises in sickle cell disorders, glomerulonephritis, alveolar haemorrhage, capillary leak syndrome, thrombocytopenia, leukocytosis and aortitis have been reported.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Myelodysplastic syndrome and acute myeloid leukaemia have been reported in patients with breast and lung cancer receiving filgrastim with chemotherapy and/or radiotherapy, and in severe chronic neutropenia.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Filgrastim: Colony-stimulating factors act on hematopoietic cells by binding to specific cell-surface receptors, stimulating proliferation, differentiation commitment and some end-cell functional activation; filgrastim mainly affects neutrophil production and function (US Neupogen label 12.1).